Abstract
Using conventional statistical analysis and multiple regression analysis, we investigated the viral and host factors that influence the response to recombinant interferon-α2a therapy in patients with chronic hepatitis C. A total of 36 patients was randomly assigned to three administration schedules, 12 patients in each. Response to treatment was set as the criterion variable. Four variables were statistically significant in the conventional method in predicting a good therapeutic outcome: HCV genotype III and IV, lower histology activity index (HAI) score for liver, higher total dose of interferon administration, and lower serum HCV RNA concentration. In multiple regression analysis, a combination of the above four variables resulted in a higher multiple correlation coefficient (R=0.84,P<0.0001) using a stepwise method. Of those four, HCV genotype had the highest absolute value of standard partial regression coefficient (0.51). The HCV RNA concentration was correlated with HCV genotype and HAI score, whereas HCV genotype and HAI score showed no correlation. Thus, HCV RNA concentration was not statistically significant in multiple regression analysis. These findings indicate that HCV genotype, HAI score, and schedule of administration can be important predictors of the response to interferon therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alter HJ: Transfusion-associated non-A, non-B hepatitis: The first decade.In Viral Hepatitis and Liver Disease. AJ Zuckerman (ed.). New York, Alan R Liss, 1988, pp 537–542
Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, Alter HJ: Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 12:671–675, 1990
Yousuf M, Nakano Y, Tanaka E, Sodeyama T, Kiyosawa K: Persistence of viremia in patient with type-C chronic hepatitis during long-term follow-up. Scand Gastroenterol 27:812–816, 1992
Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, Van Thiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, Hepatitis Interventional Therapy Group: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321:1501–1506, 1989
Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH: Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 321:1506–1510, 1989
Sen GC, Lengyel P: The interferon system. J Biol Chem 267:5017–5020, 1992
Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M, Higashi Y, Shibata M, Morishima T: Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. Hepatology 16:293–299, 1992
Okada S, Akahane Y, Suzuki H, Okamoto H, Mishiro S: The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 16:619–624, 1992
Tanaka E, Kiyosawa K, Nakatsuji Y, Inoue Y, Miyamura T, Chiba J, Furuta S: Clinical significance of antibodies to nonstructural and core proteins of hepatitis C virus in post-transfusion hepatitis patients during long-term follow-up. J Med Virol 39:318–324, 1993
Okamoto H, Okada S, Sugiyama Y, Yotsumoto S, Tanaka T, Yoshizawa H, Tsuda F, Miyakawa Y, Mayumi M: The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 60:167–177, 1990
Kwok S, Higuchi R: Avoiding false positives with PCR. Nature 339:237–238, 1989
Okamoto H, Sugiyama Y, Okada S, Kurai K, Akahane Y, Sugai Y, Tanaka T, Satoh K, Tsuda F, Miyakawa Y, Mayumi M: Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 73:673–679, 1992
Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1:431–435, 1981
Tsukiyama-Kohara K, Kohara M, Yamaguchi K, Maki N, Toyoshima A, Miki K, Tanaka S, Hattori N, Nomoto A: A second group of hepatitis C viruses. Virus Genes 5:243–254, 1991
Davis GL: Recombinant α-interferon treatment of non-A, non-B (type C) hepatitis: Review of studies and recommendations for treatment. J Hepatol 11:S72-S77, 1990
Lisker-Melman M, Di Bisceglie AM, Usala SJ, Weintraub B, Murray LM, Hoofnagle JH: Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 102:2155–2160, 1992
Silva MO, Rajender Reddy K, Jeffers LJ, Hill M, Schiff ER: Interferon-induced chronic active hepatitis? Gastroenterology 101:840–842, 1991
Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T: Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology (in press)
Author information
Authors and Affiliations
Additional information
This study was supported by a grant from the Japanese Ministry of Health and Welfare.
Rights and permissions
About this article
Cite this article
Matsumoto, A., Tanaka, E., Suzuki, T. et al. Viral and host factors that contribute to efficacy of interferon-α2a therapy in patients with chronic hepatitis C. Digest Dis Sci 39, 1273–1280 (1994). https://doi.org/10.1007/BF02093793
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02093793